2 terminated, 1 completed. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow zanolimumab: new trials by email Literature Review of zanolimumab trials Research Report on zanolimumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma HuMax-CD4 - T Cell Lymphoma | Phase 2 / Phase 3 | Completed | Emergent BioSolutions | 21 | 2005-08-01 | 2024-03-18 |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome HuMax-CD4 (zanolimumab) - Mycosis Fungoides, Sezary Syndrome | Phase 3 | Terminated | Emergent Product Development Seattle LLC | 76 | 2005-07-01 | 2012-07-26 |
| Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker HuMax-CD4, Placebo, Humax-CD4 - Rheumatoid Arthritis | Phase 2 / Phase 3 | Terminated | Genmab | 83 | 2002-03-04 | 2023-04-28 |
Arthritis, Rheumatoid (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Sezary Syndrome (1)
Emergent BioSolutions (1) · Emergent Product Development Seattle LLC (1) · Genmab (1)
United States (2) · Canada (1) · France (1) · Germany (1) · Italy (1) · Spain (1)
Abhay Patki, PhD (1)